Ververidis Athanasios N, Paraskevopoulos Konstantinos, Keskinis Anthimos, Petkidis Georgios I, Tilkeridis Konstantinos
Department of Orthopaedic Surgery, Medical School, Democritus University of Thrace, University General Hospital of Alexandroupolis, 68100, Alexandroupolis, Greece.
Medical School, Democritus University of Thrace, University General Hospital of Alexandroupolis, 68100, Alexandroupolis, Greece.
J Orthop. 2020 Nov 19;22:592-597. doi: 10.1016/j.jor.2020.11.011. eCollection 2020 Nov-Dec.
The purpose of our systematic literature review study was to critically analyze all current data including time to achieve pain relief and resolution of bone marrow edema (BME) on magnetic resonance imaging (MRI) in patients with bone marrow edema syndrome (BMES) when using bisphosphonates.
A systematic review was performed to address studies which concerned the efficacy and safety of bisphosphonates in patients with BMES. A systematic search was conducted by two investigators using databases including Pubmed and Scopus.
Nine studies were included between July 2002 and June 2019 with a total of 187 patients out of whom 150 had been treated with bisphosphonates. Mean age of patients was 44,14 (mean ranges 34.9-54.0), 113 males and 54 females (excluding one study which did not mention ages). Five studies described the outcomes from MRI on follow-up (42 out of 78 patients achieved resolution with time ranging from 3 to 12 months with a mean of 3.85 months) and eight studies described the outcomes regarding pain resolution (128 out of 140 achieved resolution with mean time 4.20 months, ranging from 0.7 months to 12 months). Adverse events related to the administration of bisphosphonates included flue-like symptoms in 6 patients, musculoskeletal pain in 1 patient, arthralgias and fever in 9 patients.
The outcome of this systematic review indicated that the effect of bisphosphonates on pain relief and on regression of BME on MRI is controversial, but due to the low level of evidence of the included studies, no definite conclusions can be acquired and no evidence based recommendation could be given.
我们的系统文献综述研究旨在严格分析所有现有数据,包括使用双膦酸盐治疗骨髓水肿综合征(BMES)患者时,磁共振成像(MRI)上实现疼痛缓解和骨髓水肿(BME)消退的时间。
进行了一项系统综述,以探讨双膦酸盐在BMES患者中的疗效和安全性。由两名研究人员使用包括PubMed和Scopus在内的数据库进行系统检索。
纳入了2002年7月至2019年6月期间的9项研究,共有187例患者,其中150例接受了双膦酸盐治疗。患者的平均年龄为44.14岁(平均范围34.9 - 54.0岁),男性113例,女性54例(不包括一项未提及年龄的研究)。五项研究描述了随访时MRI的结果(78例患者中有42例在3至12个月内实现消退,平均为3.85个月),八项研究描述了疼痛缓解的结果(140例中有128例实现缓解,平均时间为4.20个月,范围为0.7个月至12个月)。与双膦酸盐给药相关的不良事件包括6例出现流感样症状,1例出现肌肉骨骼疼痛,9例出现关节痛和发热。
该系统综述的结果表明,双膦酸盐对疼痛缓解和MRI上BME消退的作用存在争议,但由于纳入研究的证据水平较低,无法得出明确结论,也无法给出基于证据的建议。